Tau kinetics in Alzheimer's disease

Tau kinetics in Alzheimer's disease

The cytoskeletal protein tau is implicated in the pathogenesis of Alzheimer's disease which is characterized by intra-neuronal neurofibrillary tangles containing abnormally phosphorylated insoluble tau. Levels of soluble tau are elevated in the brain, the CSF, and the plasma of patients with Al...

Full description

Bibliographic Details
Main Authors:	Daniel B. Hier, Sima Azizi, Matthew S. Thimgan, Donald C. Wunsch
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Aging Neuroscience
Subjects:	tau Alzheimer's disease CSF levels plasma levels steady state kinetics halflife
Online Access:	https://www.frontiersin.org/articles/10.3389/fnagi.2022.1055170/full

Similar Items

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
by: Rik Ossenkoppele, et al.
Published: (2021-07-01)

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
by: Juan Lantero‐Rodriguez, et al.
Published: (2021-11-01)

Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
by: Juan Lantero-Rodriguez, et al.
Published: (2024-02-01)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
by: Juan Lantero-Rodriguez, et al.
Published: (2023-03-01)

Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke
by: Ann De Vos, et al.
Published: (2017-08-01)

Proteína tau como biomarcador en Alzheimer preclínico
by: Javiera Arriagada, et al.
Published: (2022-06-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-05-01)

Aqueous extractable nonfibrillar and sarkosyl extractable fibrillar Alzheimer’s disease tau seeds have distinct properties
by: Anastasie Mate de Gerando, et al.
Published: (2024-09-01)

Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
by: Edward N. Wilson, et al.
Published: (2022-11-01)

Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease
by: Javier Arranz, et al.
Published: (2024-06-01)

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
by: Fernando Gonzalez-Ortiz, et al.
Published: (2023-03-01)

Nanotechnology for tau pathology in Alzheimer's disease
by: Rongrong Ma, et al.
Published: (2024-08-01)

Enhanced neurologic concept recognition using a named entity recognition model based on transformers
by: Sima Azizi, et al.
Published: (2022-12-01)

Toxic tau: structural origins of tau aggregation in Alzheimer's disease
by: Abdullah Al Mamun, et al.
Published: (2020-01-01)

Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer’s Disease
by: Ioanna Tsantzali, et al.
Published: (2022-08-01)

CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease
by: Jeremy F. Strain, et al.
Published: (2022-06-01)

Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217
by: Branislav Kovacech, et al.
Published: (2024-11-01)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
by: Niklas Mattsson, et al.
Published: (2016-08-01)

Plasma P-Tau181 for the Discrimination of Alzheimer’s Disease from Other Primary Dementing and/or Movement Disorders
by: John S. Tzartos, et al.
Published: (2022-08-01)

Role of Body-Fluid Biomarkers in Alzheimer’s Disease Diagnosis
by: Thuy Trang Nguyen, et al.
Published: (2020-05-01)

Plasma phospho-tau217 as a predictive biomarker for Alzheimer’s disease in a large south American cohort
by: Neetesh Pandey, et al.
Published: (2025-01-01)

Using cerebrospinal fluid biomarkers to diagnose Alzheimer’s disease: an Australian perspective
by: Dhamidhu Eratne, et al.
Published: (2024-12-01)

Dynamic changes of CSF clusterin levels across the Alzheimer’s disease continuum
by: Lian Tang, et al.
Published: (2022-12-01)

Differential diagnosis of mild cognitive impairment of Alzheimer’s disease by Simoa p-tau181 measurements with matching plasma and CSF
by: Ling Wu, et al.
Published: (2024-01-01)

Implication of tau propagation on neurodegeneration in Alzheimer’s disease
by: Daniel Lamontagne-Kam, et al.
Published: (2023-07-01)

Findings of 18F‐PI‐2620 tau PET imaging in patients with Alzheimer’s disease and healthy controls in relation to the plasma P‐tau181 levels in a Japanese sample
by: Shogyoku Bun, et al.
Published: (2022-12-01)

Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platformResearch in context
by: Azadeh Feizpour, et al.
Published: (2024-11-01)

Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation
by: Yijun Chen, et al.
Published: (2023-07-01)

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected
by: Marc Suárez‐Calvet, et al.
Published: (2020-11-01)

Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer’s disease
by: Tengfei Guo, et al.
Published: (2024-07-01)

CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
by: Ruocheng Dong, et al.
Published: (2021-01-01)

Deconstructing pathological tau by biological process in early stages of Alzheimer disease: a method for quantifying tau spatial spread in neuroimagingResearch in context
by: Stephanie Doering, et al.
Published: (2024-05-01)

Fully synthetic phosphorylated Tau181, Tau217, and Tau231 calibrators for Alzheimer’s disease diagnosis
by: Xinyu Li, et al.
Published: (2024-01-01)

Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
by: Gallen Triana‐Baltzer, et al.
Published: (2021-01-01)

Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
by: Josef Marksteiner, et al.
Published: (2022-09-01)

P-tau217 as a Reliable Blood-Based Marker of Alzheimer’s Disease
by: Roy Lai, et al.
Published: (2024-08-01)

Structural study of the microtubule-associated protein tau locus of Alzheimer's disease in Taiwan
by: Chun-Wei Chang, et al.
Published: (2014-06-01)

Molecular Insights into Tau Pathology and its Therapeutic Strategies in Alzheimer's Disease
by: Futao Zhou, et al.
Published: (2024-10-01)

Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease
by: Xi-Lin Wu, et al.
Published: (2017-01-01)

Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
by: Colin Groot, et al.
Published: (2022-05-01)